These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15582984)

  • 1. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
    J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
    Zhang Z; Guo K; Schluesener HJ
    J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
    Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
    J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.
    De Fanis U; Romano C; Dalla Mora L; Sellitto A; Guastafierro S; Tirelli A; Bresciano E; Giunta R; Lucivero G
    Oncol Rep; 2003; 10(3):653-8. PubMed ID: 12684639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
    Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
    Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage.
    Slotta JE; Scheuer C; Menger MD; Vollmar B
    J Hepatol; 2006 Mar; 44(3):576-85. PubMed ID: 16310279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
    Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
    Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide IMT504 induces an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells.
    Rodriguez JM; Elias F; Montaner A; Flo J; Lopez RA; Zorzopulos J; Franco RJ; Lenial SP; Lopez Salón M; Pirpignani ML; Solimano J; Garay G; Riveros D; Fernandez J; Cacchione R; Dupont J
    Medicina (B Aires); 2006; 66(1):9-16. PubMed ID: 16555722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
    Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
    Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
    Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
    Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
    Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
    Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
    Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
    Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
    Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of CpG-oligodeoxynucleotides with Toll like receptor 9 induces apoptosis and modulates metaloproteinase-2 activity in human intestinal epithelium.
    Khorramizadeh MR; Hosseinzadeh S; Safavifar F; Saadat F; Aalizadeh N; Falak R; Jadali Z; Pezeshki M
    Iran J Allergy Asthma Immunol; 2007 Sep; 6(3):107-14. PubMed ID: 17893430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
    Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
    Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.